Reestablishment of glucose inhibition of glucagon secretion in small pseudoislets

CA Reissaus, DW Piston - Diabetes, 2017 - Am Diabetes Assoc
CA Reissaus, DW Piston
Diabetes, 2017Am Diabetes Assoc
Misregulated hormone secretion from the islet of Langerhans is central to the
pathophysiology of diabetes. Although insulin plays a key role in glucose regulation, the
importance of glucagon is increasingly acknowledged. However, the mechanisms that
regulate glucagon secretion from α-cells are still unclear. We used pseudoislets
reconstituted from dispersed islet cells to study α-cells with and without various indirect
effects from other islet cells. Dispersed islet cells secrete aberrant levels of glucagon and …
Misregulated hormone secretion from the islet of Langerhans is central to the pathophysiology of diabetes. Although insulin plays a key role in glucose regulation, the importance of glucagon is increasingly acknowledged. However, the mechanisms that regulate glucagon secretion from α-cells are still unclear. We used pseudoislets reconstituted from dispersed islet cells to study α-cells with and without various indirect effects from other islet cells. Dispersed islet cells secrete aberrant levels of glucagon and insulin at basal and elevated glucose levels. When cultured, murine islet cells reassociate to form pseudoislets, which recover normal glucose-regulated hormone secretion, and human islet cells follow a similar pattern. We created small (∼40-µm) pseudoislets using all of the islet cells or only some of the cell types, which allowed us to characterize novel aspects of regulated hormone secretion. The recovery of regulated glucagon secretion from α-cells in small pseudoislets depends upon the combined action of paracrine factors, such as insulin and somatostatin, and juxtacrine signals between EphA4/7 on α-cells and ephrins on β-cells. Although these signals modulate different pathways, both appear to be required for proper inhibition of glucagon secretion in response to glucose. This improved understanding of the modulation of glucagon secretion can provide novel therapeutic routes for the treatment of some individuals with diabetes.
Am Diabetes Assoc